Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
International Journal of Cancer|June 9, 2025
Safety and efficacy of docosahexaenoic acid supplementation during neoadjuvant breast cancer therapy: Findings from the phase II, double-blind, randomized controlled DHA-WIN trialJaqueline Munhoz, Marnie Newell, Gilbert Bigras, et al.Cell Reports. Medicine|November 10, 2021
Genome profiles of pathologist-defined cell clusters by multiregional LCM and G&T-seq in one triple-negative breast cancer patientZhongyi Zhu, Weiwei Wang, Feng Lin, et al.Current Oncology (Toronto, Ont.)|November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast CancerJeffrey Q Cao, Brae Surgeoner, Mita Manna, et al.Current Oncology (Toronto, Ont.)|April 27, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update)Aalok Kumar, Katarzyna J Jerzak, Karen A Gelmon, et al.Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025Sandeep Sehdev, Anil Abraham Joy, Jean-François Boileau, et al.Cancer Research Communications|October 22, 2025
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast CancerAnil Abraham Joy, Nicholas Cheng, Karen A Gelmon, et al.JAMA Oncology|November 17, 2022
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled TrialTimothy A Yap, Aditya Bardia, Michael Dvorkin, et al.Current Oncology (Toronto, Ont.)|November 26, 2024
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic SettingMita Manna, Karen A Gelmon, Jean-François Boileau, et al.BMJ Open|September 19, 2019
Comparing docosahexaenoic acid (DHA) concomitant with neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in the treatment of breast cancer (DHA WIN): protocol of a double-blind, phase II, randomised controlled trialMarnie Newell, John R Mackey, Gilbert Bigras, et al.Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025Katarzyna J Jerzak, Aalok Kumar, Jean-François Boileau, et al.Pageof 9